EGFR and non-small cell lung carcinoma: 32 also analyzed the subsequent treatment after resistance to EGFR‐TKI, the results showed that the PFS2 in the patients with T790M mutation was 6.2 months, which was significantly longer than 2.6 months in the patients without T790M mutation (P = 0.002). Nowadays, several promising new agents such as CO1686 and AZD9291 that target T790M showed amazing results. And AZD9291 has been approved by FDA for the treatment of patients with metastatic EGFR T790M mutation‐positive NSCLC who have progressed on or after EGFR‐TKI therapy 43.